Last 12 months
Inside the activity.
6 purchase rows · 11 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 3 |
| Dec 2025 | 3 | 0 |
| Jan 2026 | 0 | 4 |
| Feb 2026 | 0 | 4 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 3 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 21, 2021 Filed Apr 23, 2021 20:06 UTC |
KANE MATTHEW R.Director · President and CEO
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 13,422 | $0.00 Strike: $1.18 | $0.00 |
DisclosureSEC source: 0001209191-21-028105 · doc4.xml · derivative · entry 3 KANE MATTHEW R. · CIK 0001769887 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,422 shares Expires 2027-03-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| April 21, 2021 Filed Apr 23, 2021 20:06 UTC |
KANE MATTHEW R.Director · President and CEO
|
Exercise / conversionCommon Stock | 13,422 | $1.18 | $15,837.96 |
DisclosureSEC source: 0001209191-21-028105 · doc4.xml · nonDerivative · entry 1 KANE MATTHEW R. · CIK 0001769887 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,978,218 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 19, 2021 Filed Apr 21, 2021 20:11 UTC |
JANTZ DEREKDirector · Chief Scientific Officer
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 21,514 | $0.00 Strike: $0.04 | $0.00 |
DisclosureSEC source: 0001209191-21-027770 · doc4.xml · derivative · entry 3 JANTZ DEREK · CIK 0001769828 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,542 Underlying: Common Stock · 21,514 shares Expires 2021-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| April 19, 2021 Filed Apr 21, 2021 20:11 UTC |
JANTZ DEREKDirector · Chief Scientific Officer
|
SaleCommon Stock | 9,676 | $8.69 | $84,084.44 |
DisclosureSEC source: 0001209191-21-027770 · doc4.xml · nonDerivative · entry 2 JANTZ DEREK · CIK 0001769828 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,016,759 F1 · kind: All sales were effected pursuant to a Rule 10b5-1 plan. The transaction was a sell-to-cover exercise, with shares sold to cover the option exercise price and taxes, and the reporting person retaining all remaining shares. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.63 to $8.69. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 19, 2021 Filed Apr 21, 2021 20:11 UTC |
JANTZ DEREKDirector · Chief Scientific Officer
|
Exercise / conversionCommon Stock | 21,514 | $0.04 | $860.56 |
DisclosureSEC source: 0001209191-21-027770 · doc4.xml · nonDerivative · entry 1 JANTZ DEREK · CIK 0001769828 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,026,435 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 16, 2021 Filed Apr 19, 2021 20:06 UTC |
JANTZ DEREKDirector · Chief Scientific Officer
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 21,514 | $0.00 Strike: $0.04 | $0.00 |
DisclosureSEC source: 0001209191-21-027265 · doc4.xml · derivative · entry 6 JANTZ DEREK · CIK 0001769828 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,056 Underlying: Common Stock · 21,514 shares Expires 2021-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| April 16, 2021 Filed Apr 19, 2021 20:06 UTC |
JANTZ DEREKDirector · Chief Scientific Officer
|
SaleCommon Stock | 9,675 | $8.84 | $85,527.00 |
DisclosureSEC source: 0001209191-21-027265 · doc4.xml · nonDerivative · entry 4 JANTZ DEREK · CIK 0001769828 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,004,921 F1 · kind: All sales were effected pursuant to a Rule 10b5-1 plan. The transaction was a sell-to-cover exercise, with shares sold to cover the option exercise price and taxes, and the reporting person retaining all remaining shares. Read SEC document |
| April 16, 2021 Filed Apr 19, 2021 20:06 UTC |
JANTZ DEREKDirector · Chief Scientific Officer
|
Exercise / conversionCommon Stock | 21,514 | $0.04 | $860.56 |
DisclosureSEC source: 0001209191-21-027265 · doc4.xml · nonDerivative · entry 3 JANTZ DEREK · CIK 0001769828 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,014,596 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 15, 2021 Filed Apr 19, 2021 20:06 UTC |
JANTZ DEREKDirector · Chief Scientific Officer
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 21,514 | $0.00 Strike: $0.04 | $0.00 |
DisclosureSEC source: 0001209191-21-027265 · doc4.xml · derivative · entry 5 JANTZ DEREK · CIK 0001769828 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,570 Underlying: Common Stock · 21,514 shares Expires 2021-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| April 15, 2021 Filed Apr 19, 2021 20:06 UTC |
JANTZ DEREKDirector · Chief Scientific Officer
|
SaleCommon Stock | 9,676 | $8.76 | $84,761.76 |
DisclosureSEC source: 0001209191-21-027265 · doc4.xml · nonDerivative · entry 2 JANTZ DEREK · CIK 0001769828 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,993,082 F1 · kind: All sales were effected pursuant to a Rule 10b5-1 plan. The transaction was a sell-to-cover exercise, with shares sold to cover the option exercise price and taxes, and the reporting person retaining all remaining shares. Read SEC document |
| April 15, 2021 Filed Apr 19, 2021 20:06 UTC |
JANTZ DEREKDirector · Chief Scientific Officer
|
Exercise / conversionCommon Stock | 21,514 | $0.04 | $860.56 |
DisclosureSEC source: 0001209191-21-027265 · doc4.xml · nonDerivative · entry 1 JANTZ DEREK · CIK 0001769828 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,002,758 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 12, 2021 Filed Apr 14, 2021 20:31 UTC |
Frankel StanleyDirector
|
GrantStock Option (Right to Buy) · Derivative | 63,325 | $0.00 Strike: $8.36 | $0.00 |
DisclosureSEC source: 0001209191-21-026660 · doc4.xml · derivative · entry 1 Frankel Stanley · CIK 0001855726 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,325 Underlying: Common Stock · 63,325 shares Expires 2031-04-11 F1 · derivative.exercise_date: The option vests in 36 substantially equal monthly installments following April 12, 2021, such that the option shall be fully vested on April 12, 2024. Read SEC document |
| April 12, 2021 Filed Apr 14, 2021 20:37 UTC |
KANE MATTHEW R.Director · President and CEO
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 21,514 | $0.00 Strike: $0.04 | $0.00 |
DisclosureSEC source: 0001209191-21-026663 · doc4.xml · derivative · entry 4 KANE MATTHEW R. · CIK 0001769887 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,542 Underlying: Common Stock · 21,514 shares Expires 2021-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| April 12, 2021 Filed Apr 14, 2021 20:37 UTC |
KANE MATTHEW R.Director · President and CEO
|
SaleCommon Stock | 9,741 | $8.67 | $84,454.47 |
DisclosureSEC source: 0001209191-21-026663 · doc4.xml · nonDerivative · entry 2 KANE MATTHEW R. · CIK 0001769887 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,964,796 F1 · kind: All sales were effected pursuant to a Rule 10b5-1 plan. The transaction was a sell-to-cover exercise, with shares sold to cover the option exercise price and taxes, and the reporting person retaining all remaining shares. Read SEC document |
| April 12, 2021 Filed Apr 14, 2021 20:37 UTC |
KANE MATTHEW R.Director · President and CEO
|
Exercise / conversionCommon Stock | 21,514 | $0.04 | $860.56 |
DisclosureSEC source: 0001209191-21-026663 · doc4.xml · nonDerivative · entry 1 KANE MATTHEW R. · CIK 0001769887 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,974,537 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 09, 2021 Filed Apr 12, 2021 21:06 UTC |
KANE MATTHEW R.Director · President and CEO
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 21,514 | $0.00 Strike: $0.04 | $0.00 |
DisclosureSEC source: 0001209191-21-026375 · doc4.xml · derivative · entry 7 KANE MATTHEW R. · CIK 0001769887 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,056 Underlying: Common Stock · 21,514 shares Expires 2021-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| April 09, 2021 Filed Apr 12, 2021 21:06 UTC |
KANE MATTHEW R.Director · President and CEO
|
SaleCommon Stock | 9,737 | $8.87 | $86,367.19 |
DisclosureSEC source: 0001209191-21-026375 · doc4.xml · nonDerivative · entry 4 KANE MATTHEW R. · CIK 0001769887 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,953,023 F1 · kind: All sales were effected pursuant to a Rule 10b5-1 plan. The transaction was a sell-to-cover exercise, with shares sold to cover the option exercise price and taxes, and the reporting person retaining all remaining shares. Read SEC document |
| April 09, 2021 Filed Apr 12, 2021 21:06 UTC |
KANE MATTHEW R.Director · President and CEO
|
Exercise / conversionCommon Stock | 21,514 | $0.04 | $860.56 |
DisclosureSEC source: 0001209191-21-026375 · doc4.xml · nonDerivative · entry 3 KANE MATTHEW R. · CIK 0001769887 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,962,760 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 08, 2021 Filed Apr 12, 2021 21:06 UTC |
KANE MATTHEW R.Director · President and CEO
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 21,514 | $0.00 Strike: $0.04 | $0.00 |
DisclosureSEC source: 0001209191-21-026375 · doc4.xml · derivative · entry 6 KANE MATTHEW R. · CIK 0001769887 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,570 Underlying: Common Stock · 21,514 shares Expires 2021-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| April 08, 2021 Filed Apr 12, 2021 21:06 UTC |
KANE MATTHEW R.Director · President and CEO
|
SaleCommon Stock | 9,736 | $9.00 | $87,624.00 |
DisclosureSEC source: 0001209191-21-026375 · doc4.xml · nonDerivative · entry 2 KANE MATTHEW R. · CIK 0001769887 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,941,246 F1 · kind: All sales were effected pursuant to a Rule 10b5-1 plan. The transaction was a sell-to-cover exercise, with shares sold to cover the option exercise price and taxes, and the reporting person retaining all remaining shares. Read SEC document |
| April 08, 2021 Filed Apr 12, 2021 21:06 UTC |
KANE MATTHEW R.Director · President and CEO
|
Exercise / conversionCommon Stock | 21,514 | $0.04 | $860.56 |
DisclosureSEC source: 0001209191-21-026375 · doc4.xml · nonDerivative · entry 1 KANE MATTHEW R. · CIK 0001769887 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,950,982 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 18, 2021 Filed Mar 22, 2021 20:12 UTC |
JANTZ DEREKDirector · Chief Scientific Officer
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 21,514 | $0.00 Strike: $0.04 | $0.00 |
DisclosureSEC source: 0001209191-21-022324 · doc4.xml · derivative · entry 3 JANTZ DEREK · CIK 0001769828 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,084 Underlying: Common Stock · 21,514 shares Expires 2021-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| March 18, 2021 Filed Mar 22, 2021 20:12 UTC |
JANTZ DEREKDirector · Chief Scientific Officer
|
SaleCommon Stock | 9,665 | $11.08 | $107,088.20 |
DisclosureSEC source: 0001209191-21-022324 · doc4.xml · nonDerivative · entry 2 JANTZ DEREK · CIK 0001769828 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,981,244 F1 · kind: All sales were effected pursuant to a Rule 10b5-1 plan. The transaction was a sell-to-cover exercise, with shares sold to cover the option exercise price and taxes, and the reporting person retaining all remaining shares. Read SEC document |
| March 18, 2021 Filed Mar 22, 2021 20:12 UTC |
JANTZ DEREKDirector · Chief Scientific Officer
|
Exercise / conversionCommon Stock | 21,514 | $0.04 | $860.56 |
DisclosureSEC source: 0001209191-21-022324 · doc4.xml · nonDerivative · entry 1 JANTZ DEREK · CIK 0001769828 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,990,909 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 17, 2021 Filed Mar 18, 2021 20:05 UTC |
JANTZ DEREKDirector · Chief Scientific Officer
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 21,514 | $0.00 Strike: $0.04 | $0.00 |
DisclosureSEC source: 0001209191-21-021747 · doc4.xml · derivative · entry 6 JANTZ DEREK · CIK 0001769828 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,598 Underlying: Common Stock · 21,514 shares Expires 2021-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| March 17, 2021 Filed Mar 18, 2021 20:05 UTC |
JANTZ DEREKDirector · Chief Scientific Officer
|
SaleCommon Stock | 9,665 | $10.92 | $105,541.80 |
DisclosureSEC source: 0001209191-21-021747 · doc4.xml · nonDerivative · entry 4 JANTZ DEREK · CIK 0001769828 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,969,395 F1 · kind: All sales were effected pursuant to a Rule 10b5-1 plan. The transaction was a sell-to-cover exercise, with shares sold to cover the option exercise price and taxes, and the reporting person retaining all remaining shares. Read SEC document |
| March 17, 2021 Filed Mar 18, 2021 20:05 UTC |
JANTZ DEREKDirector · Chief Scientific Officer
|
Exercise / conversionCommon Stock | 21,514 | $0.04 | $860.56 |
DisclosureSEC source: 0001209191-21-021747 · doc4.xml · nonDerivative · entry 3 JANTZ DEREK · CIK 0001769828 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,979,060 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 16, 2021 Filed Mar 18, 2021 20:05 UTC |
JANTZ DEREKDirector · Chief Scientific Officer
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 21,514 | $0.00 Strike: $0.04 | $0.00 |
DisclosureSEC source: 0001209191-21-021747 · doc4.xml · derivative · entry 5 JANTZ DEREK · CIK 0001769828 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,112 Underlying: Common Stock · 21,514 shares Expires 2021-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| March 16, 2021 Filed Mar 18, 2021 20:05 UTC |
JANTZ DEREKDirector · Chief Scientific Officer
|
SaleCommon Stock | 9,661 | $11.97 | $115,642.17 |
DisclosureSEC source: 0001209191-21-021747 · doc4.xml · nonDerivative · entry 2 JANTZ DEREK · CIK 0001769828 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,957,546 F1 · kind: All sales were effected pursuant to a Rule 10b5-1 plan. The transaction was a sell-to-cover exercise, with shares sold to cover the option exercise price and taxes, and the reporting person retaining all remaining shares. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.92 to $11.98. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 16, 2021 Filed Mar 18, 2021 20:05 UTC |
JANTZ DEREKDirector · Chief Scientific Officer
|
Exercise / conversionCommon Stock | 21,514 | $0.04 | $860.56 |
DisclosureSEC source: 0001209191-21-021747 · doc4.xml · nonDerivative · entry 1 JANTZ DEREK · CIK 0001769828 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,967,207 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 12, 2021 Filed Mar 16, 2021 20:34 UTC |
KANE MATTHEW R.Director · President and CEO
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 21,514 | $0.00 Strike: $0.04 | $0.00 |
DisclosureSEC source: 0001209191-21-020823 · doc4.xml · derivative · entry 4 KANE MATTHEW R. · CIK 0001769887 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,084 Underlying: Common Stock · 21,514 shares Expires 2021-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| March 12, 2021 Filed Mar 16, 2021 20:34 UTC |
KANE MATTHEW R.Director · President and CEO
|
SaleCommon Stock | 9,712 | $11.36 | $110,328.32 |
DisclosureSEC source: 0001209191-21-020823 · doc4.xml · nonDerivative · entry 2 KANE MATTHEW R. · CIK 0001769887 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,929,468 F1 · kind: All sales were effected pursuant to a Rule 10b5-1 plan. The transaction was a sell-to-cover exercise, with shares sold to cover the option exercise price and taxes, and the reporting person retaining all remaining shares. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.36 to $11.38. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 12, 2021 Filed Mar 16, 2021 20:34 UTC |
KANE MATTHEW R.Director · President and CEO
|
Exercise / conversionCommon Stock | 21,514 | $0.04 | $860.56 |
DisclosureSEC source: 0001209191-21-020823 · doc4.xml · nonDerivative · entry 1 KANE MATTHEW R. · CIK 0001769887 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,939,180 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 11, 2021 Filed Mar 12, 2021 23:03 UTC |
KANE MATTHEW R.Director · President and CEO
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 21,514 | $0.00 Strike: $0.04 | $0.00 |
DisclosureSEC source: 0001209191-21-020273 · doc4.xml · derivative · entry 7 KANE MATTHEW R. · CIK 0001769887 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,598 Underlying: Common Stock · 21,514 shares Expires 2021-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| March 11, 2021 Filed Mar 12, 2021 23:03 UTC |
KANE MATTHEW R.Director · President and CEO
|
SaleCommon Stock | 9,711 | $11.38 | $110,511.18 |
DisclosureSEC source: 0001209191-21-020273 · doc4.xml · nonDerivative · entry 4 KANE MATTHEW R. · CIK 0001769887 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,917,666 F2 · kind: All sales were effected pursuant to a Rule 10b5-1 plan. The transaction was a sell-to-cover exercise, with shares sold to cover the option exercise price and taxes, and the reporting person retaining all remaining shares. Read SEC document |
| March 11, 2021 Filed Mar 12, 2021 23:03 UTC |
KANE MATTHEW R.Director · President and CEO
|
Exercise / conversionCommon Stock | 21,514 | $0.04 | $860.56 |
DisclosureSEC source: 0001209191-21-020273 · doc4.xml · nonDerivative · entry 3 KANE MATTHEW R. · CIK 0001769887 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,927,377 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 23:03 UTC |
KANE MATTHEW R.Director · President and CEO
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 21,514 | $0.00 Strike: $0.04 | $0.00 |
DisclosureSEC source: 0001209191-21-020273 · doc4.xml · derivative · entry 6 KANE MATTHEW R. · CIK 0001769887 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,112 Underlying: Common Stock · 21,514 shares Expires 2021-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 23:03 UTC |
KANE MATTHEW R.Director · President and CEO
|
SaleCommon Stock | 9,710 | $11.79 | $114,480.90 |
DisclosureSEC source: 0001209191-21-020273 · doc4.xml · nonDerivative · entry 2 KANE MATTHEW R. · CIK 0001769887 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,905,863 F2 · kind: All sales were effected pursuant to a Rule 10b5-1 plan. The transaction was a sell-to-cover exercise, with shares sold to cover the option exercise price and taxes, and the reporting person retaining all remaining shares. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.61 to $11.80. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 23:03 UTC |
KANE MATTHEW R.Director · President and CEO
|
Exercise / conversionCommon Stock | 21,514 | $0.04 | $860.56 |
DisclosureSEC source: 0001209191-21-020273 · doc4.xml · nonDerivative · entry 1 KANE MATTHEW R. · CIK 0001769887 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,915,573 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 4,613 additional shares acquired under the Company's 2019 Employee Stock Purchase Plan since the Reporting Person's ownership report filed on February 22, 2021. Read SEC document |
| February 26, 2021 Filed Mar 7, 2022 16:14 UTC |
Scimeca DarioGeneral Counsel and Secretary
|
GrantCommon Stock | 2,748 | $4.61 | $12,668.28 |
DisclosureSEC source: 0001209191-22-016629 · doc4.xml · nonDerivative · entry 3 Scimeca Dario · CIK 0001779581 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,976 Read SEC document |
| February 26, 2021 Filed Mar 7, 2022 21:22 UTC |
Barton ShaneVP & Corporate Controller
|
GrantCommon Stock | 1,294 | $4.61 | $5,965.34 |
DisclosureSEC source: 0001209191-22-016641 · doc4.xml · nonDerivative · entry 1 Barton Shane · CIK 0001836297 · VP & Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,294 Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 22:46 UTC |
JANTZ DEREKDirector · Chief Scientific Officer
|
SaleCommon Stock | 9,660 | $12.04 | $116,306.40 |
DisclosureSEC source: 0001209191-21-013922 · doc4.xml · nonDerivative · entry 2 JANTZ DEREK · CIK 0001769828 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,945,693 F1 · kind: All sales were effected pursuant to a Rule 10b5-1 plan. The transaction was a sell-to-cover exercise, with shares sold to cover the option exercise price and taxes, and the reporting person retaining all remaining shares. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.00 to $12.08. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 22:46 UTC |
JANTZ DEREKDirector · Chief Scientific Officer
|
Exercise / conversionCommon Stock | 21,514 | $0.04 | $860.56 |
DisclosureSEC source: 0001209191-21-013922 · doc4.xml · nonDerivative · entry 1 JANTZ DEREK · CIK 0001769828 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,955,353 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 00:03 UTC |
JANTZ DEREKDirector · Chief Scientific Officer
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 21,514 | $0.00 Strike: $0.04 | $0.00 |
DisclosureSEC source: 0001209191-21-012911 · doc4.xml · derivative · entry 6 JANTZ DEREK · CIK 0001769828 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,140 Underlying: Common Stock · 21,514 shares Expires 2021-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 00:03 UTC |
JANTZ DEREKDirector · Chief Scientific Officer
|
SaleCommon Stock | 9,663 | $11.55 | $111,607.65 |
DisclosureSEC source: 0001209191-21-012911 · doc4.xml · nonDerivative · entry 4 JANTZ DEREK · CIK 0001769828 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,933,839 F1 · kind: All sales were effected pursuant to a Rule 10b5-1 plan. The transaction was a sell-to-cover exercise, with shares sold to cover the option exercise price and taxes, and the reporting person retaining all remaining shares. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.53 to $11.61. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 00:03 UTC |
JANTZ DEREKDirector · Chief Scientific Officer
|
Exercise / conversionCommon Stock | 21,514 | $0.04 | $860.56 |
DisclosureSEC source: 0001209191-21-012911 · doc4.xml · nonDerivative · entry 3 JANTZ DEREK · CIK 0001769828 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,943,502 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 18, 2021 Filed Feb 23, 2021 00:03 UTC |
JANTZ DEREKDirector · Chief Scientific Officer
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 21,514 | $0.00 Strike: $0.04 | $0.00 |
DisclosureSEC source: 0001209191-21-012911 · doc4.xml · derivative · entry 5 JANTZ DEREK · CIK 0001769828 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,654 Underlying: Common Stock · 21,514 shares Expires 2021-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| February 18, 2021 Filed Feb 23, 2021 00:03 UTC |
JANTZ DEREKDirector · Chief Scientific Officer
|
SaleCommon Stock | 6,871 | $12.20 | $83,826.20 |
DisclosureSEC source: 0001209191-21-012911 · doc4.xml · nonDerivative · entry 2 JANTZ DEREK · CIK 0001769828 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,921,988 F1 · kind: All sales were effected pursuant to a Rule 10b5-1 plan. The transaction was a sell-to-cover exercise, with shares sold to cover the option exercise price and taxes, and the reporting person retaining all remaining shares. Read SEC document |
| February 18, 2021 Filed Feb 23, 2021 00:03 UTC |
JANTZ DEREKDirector · Chief Scientific Officer
|
Exercise / conversionCommon Stock | 21,514 | $0.04 | $860.56 |
DisclosureSEC source: 0001209191-21-012911 · doc4.xml · nonDerivative · entry 1 JANTZ DEREK · CIK 0001769828 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,928,859 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 21:45 UTC |
KANE MATTHEW R.Director · President and CEO
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 21,514 | $0.00 Strike: $0.04 | $0.00 |
DisclosureSEC source: 0001209191-21-012745 · doc4.xml · derivative · entry 4 KANE MATTHEW R. · CIK 0001769887 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,626 Underlying: Common Stock · 21,514 shares Expires 2021-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.